The overall goal of the present study is to determine whether Omega-3 Fatty Acids potentially
prevent onset of psychosis and improve clinical symptoms and functional outcome in youth and
young adults at elevated clinical risk for schizophrenia and related disorders. The specific
aims are: (1) To determine whether the rate of progression to psychosis is lower during six
months of treatment with Omega-3 Fatty Acids compared to six months of treatment with
placebo, (2) To determine whether Omega-3 Fatty Acids are more efficacious than placebo for
prodromal symptoms, negative symptoms, and functioning, (3) To assess the safety and
tolerability of Omega-3 Fatty Acids in this population, and (4) To conduct analyses of
neuroimaging, neurocognitive, electrophysiological and other ancillary data to explore
mechanistic explanations for the hypothesized benefits of Omega-3 Fatty Acids on clinical and
functional outcomes (e.g., increases in white matter integrity and processing speed).